GE announced plans on Monday to sell its BioPharma business to Danaher for approximately $21.4 billion, including $21 billion in cash. GE Chairman and CEO H. Lawrence Culp Jr. said the deal was a “pivotal milestone” that “demonstrates that we are executing on our strategy by taking thoughtful and deliberate action to reduce leverage and strengthen our balance sheet.”
- When fully operational, new facility will house more than 500 highly skilled employees and bring more than 220 new jobs to Massachusetts
- Long-term investment places new US business headquarters at the heart of the most dynamic and growing life sciences, healthcare and biotech cluster in the US
- Furthers GE Healthcare Life Sciences' leadership in molecular and precision medicine, clinical diagnostics, manufacturing and R&D
MARLBOROUGH, Mass., Aug.
business unit
tags
Princeton, NJ -- May 30, 2014 -- Effective from June 1st 2014 and following approval by the US Food and Drug Administration (FDA), GE Healthcare today announced the intent to supply generators for the production of sodium pertechnetate; technetium (Tc99m) injection to its radiopharmacies in the US.